3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Neoplasms
2
Mycosis Fungoides
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Interventions
Cyclophosphamide
17
Etoposide
10
fludarabine
9
Whole-Body Irradiation
9
Brentuximab Vedotin
9
Melphalan
8
fludarabine phosphate
7
Vincristine
7
Mycophenolic Acid
7
Gemcitabine
7
Doxorubicin
7
Prednisone
6
Granulocyte Colony-Stimulating Factor
6
Busulfan
6
Vorinostat
5
Rituximab
5
Peripheral Blood Stem Cell Transplantation
5
Lenalidomide
5
Filgrastim
5
Cytarabine
5
Bortezomib
5
romidepsin
4
pembrolizumab
4
duvelisib
4
Tacrolimus
4
Stem Cell Transplantation
4
Carmustine
4
etoposide phosphate
3
Sirolimus
3
Dexamethasone
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Lymphoma, T-Cell
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled